D-1096-2018 Class II Terminated

Recalled by Northwind Pharmaceuticals LLC — Indianapolis, IN

FDA drug recall D-1096-2018 was initiated by Northwind Pharmaceuticals LLC on Jul 18, 2018 and is designated Class II. Reason for recall: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. The recall status is terminated (terminated Mar 25, 2023). Affected quantity: 43 bottles.

Recall details

Product Type
Drugs
Report Date
Aug 22, 2018
Initiation Date
Jul 18, 2018
Termination Date
Mar 25, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
43 bottles

Product description

Valsartan HCTZ, 160/12.5mg, 30 tablets per bottle, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46256. NDC: 51655-950-52

Reason for recall

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Distribution pattern

Indiana

Code information

Lot: UTB23790003, exp 02/28/2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1096-2018
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1096-2018. Report a data issue: hello@regdatalab.com.